StreetInsider.com News Articles

Alto Neuroscience Announces Participation in Upcoming Investor Conferences

Wed, 09 Sep 2026 08:03:00 -0400

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company’s management team will participate in the following upcoming investor conferences:

H.C. Wainwright 28th Annual Global Healthcare Conference, September 14-16, 2026
- Format: Fireside chat and one-on-one meetings
- Presentation Date & Time: September 14, 2026, 9:30 am ET
- Location: New York, NY and virtual

Baird’s 2026 Global Healthcare Conference, September 15, 2026
- Format: Company presentation and one-on-one meetings
- Presentation Date & Time: September 15, 2026, 9:40 am ET
- Location: New York,

Alto Neuroscience Announces Participation in Upcoming Investor Conferences

Wed, 09 Sep 2026 08:03:00 -0400

H.C. Wainwright 28th Annual Global Healthcare Conference, September 14-16, 2026
- Format: Fireside chat and one-on-one meetings
- Presentation Date & Time: September 14, 2026, 9:30 am ET
- Location: New York, NY and virtual

Baird’s 2026 Global Healthcare Conference, September 15, 2026
- Format: Company presentation and one-on-one meetings
- Presentation Date & Time: September 15, 2026, 9:40 am ET
- Location: New York,

Form 8-K Alto Neuroscience, Inc. For: Aug 26

Thu, 27 Aug 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260827/26991236.html

Form 8-K Alto Neuroscience, Inc. For: Aug 26

Thu, 27 Aug 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260827/26991236.html

Alto Neuroscience promotes Nick Smith to president and CFO

Thu, 27 Aug 2026 16:05:55 -0400

Alto Neuroscience, Inc. (NYSE: ANRO) has promoted Nick Smith to president and chief financial officer, effective August 26, 2026, according to a company statement.

Smith will continue to oversee Alto's finance function while also leading corporate strategy and business development. He will report to Amit Etkin, M.D., Ph.D., the company's founder, chief executive officer, and chair of the board of directors.

Smith joined Alto in 2021 as chief business officer and has served as chief financial officer since 2022. During that period, he led the company's initial public offering, the acquisition of ALTO-207 in May 2025, and subsequent financings related to that

Alto Neuroscience promotes Nick Smith to president and CFO

Thu, 27 Aug 2026 16:05:55 -0400

Alto Neuroscience, Inc. (NYSE: ANRO) has promoted Nick Smith to president and chief financial officer, effective August 26, 2026, according to a company statement.

Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer

Thu, 27 Aug 2026 16:05:00 -0400

Expanded role reflects leadership across finance, corporate strategy, and business development

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company developing novel precision medicines for neuropsychiatric disorders, today announced the promotion of Nick Smith to president and chief financial officer, effective August 26, 2026.

Mr. Smith will continue to lead Alto’s finance function and oversee corporate strategy and business development, reporting to Amit Etkin, M.D., Ph.D., Alto’s founder, chief executive officer and chair of the board of directors.

Mr. Smith joined Alto in 2021 as chief business officer and has served as chief financial officer

Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer

Thu, 27 Aug 2026 16:05:00 -0400

Expanded role reflects leadership across finance, corporate strategy, and business development

Mr. Smith joined Alto in 2021 as chief business officer and has served as chief financial officer

Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer

Thu, 27 Aug 2026 16:05:00 -0400

Expanded role reflects leadership across finance, corporate strategy, and business development

Mr. Smith joined Alto in 2021 as chief business officer and has served as chief financial officer

Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer

Thu, 27 Aug 2026 16:05:00 -0400

Expanded role reflects leadership across finance, corporate strategy, and business development

Mr. Smith joined Alto in 2021 as chief business officer and has served as chief financial officer

Alto Neuroscience (ANRO) PT Raised to $55 at H.C. Wainwright

Tue, 18 Aug 2026 06:40:45 -0400

(Updated - August 18, 2026 6:40 AM EDT)

H.C. Wainwright analyst Patrick Trucchio raised the price target on Alto Neuroscience (NYSE: ANRO) to $55.00 (from $50.00) while maintaining a Buy rating.

The analyst commented: "On August 12, Alto reported 2Q26 results and named its ALTO-207 development plan the PACE program (Pramipexole-ondansetron Assessment of Clinical Efficacy in depression), a three-trial plan covering both adjunctive and monotherapy TRD: PACE-1, the ongoing, potentially registrational Phase 2b trial evaluating ALTO-207 as an adjunctive treatment in approximately 178 adults with TRD, enrolling on track with topline data expected in 2H27; PACE-2, the Phase 3 trial evaluating ALTO-207

Alto Neuroscience (ANRO) PT Raised to $55 at H.C. Wainwright

Tue, 18 Aug 2026 06:40:45 -0400

(Updated - August 18, 2026 6:40 AM EDT)

H.C. Wainwright analyst Patrick Trucchio raised the price target on Alto Neuroscience (NYSE: ANRO) to $55.00 (from $50.00) while maintaining a Buy rating.

Form SCHEDULE 13G/A Alto Neuroscience, Inc. Filed by: PERCEPTIVE ADVISORS LLC

Fri, 14 Aug 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260814/26932802.html

Form SCHEDULE 13G/A Alto Neuroscience, Inc. Filed by: PERCEPTIVE ADVISORS LLC

Fri, 14 Aug 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260814/26932802.html

Form SCHEDULE 13G/A Alto Neuroscience, Inc. Filed by: Vestal Point Capital, LP

Fri, 14 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260814/26930392.html

Form SCHEDULE 13G/A Alto Neuroscience, Inc. Filed by: Vestal Point Capital, LP

Fri, 14 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260814/26930392.html

Form SCHEDULE 13G/A Alto Neuroscience, Inc. Filed by: Sirenia Capital Management LP

Fri, 14 Aug 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260814/26925149.html

Form SCHEDULE 13G/A Alto Neuroscience, Inc. Filed by: Sirenia Capital Management LP

Fri, 14 Aug 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260814/26925149.html

Alto Neuroscience, Inc. (ANRO) Tops Q2 EPS by 10c

Wed, 12 Aug 2026 17:16:05 -0400

Alto Neuroscience, Inc. (NYSE: ANRO) reported Q2 EPS of ($0.65), $0.10 better than the analyst estimate of ($0.75).

For earnings history and earnings-related data on Alto Neuroscience, Inc. (ANRO) click here.

Form 10-Q Alto Neuroscience, Inc. For: Jun 30

Wed, 12 Aug 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260812/26913395.html

Form 10-Q Alto Neuroscience, Inc. For: Jun 30

Wed, 12 Aug 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260812/26913395.html

Form 8-K Alto Neuroscience, Inc. For: Aug 12

Wed, 12 Aug 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260812/26913016.html

Form 8-K Alto Neuroscience, Inc. For: Aug 12

Wed, 12 Aug 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260812/26913016.html

Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Wed, 12 Aug 2026 16:03:00 -0400

– ALTO-207 development expanded: an additional Phase 3 trial evaluating ALTO-207 as monotherapy in treatment-resistant depression (TRD) is now planned, alongside the ongoing potentially registrational Phase 2b trial; topline Phase 2b data on track for 2H 2027 –

– Independent investigator-led study results published in Nature Medicine reinforce the dopaminergic mechanism underlying ALTO-207, demonstrating significant effects on anhedonia (Hedges' g=0.62, p=0.006) –

– Approximately $100 million financing completed in July 2026; pro forma cash of approximately $338 million expected to fund planned operations through 2030 –

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a

Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Wed, 12 Aug 2026 16:03:00 -0400

– Approximately $100 million financing completed in July 2026; pro forma cash of approximately $338 million expected to fund planned operations through 2030 –

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a